EP
RXRX icon

Essential Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Essential Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-615
Closed -$2.26K – 2978
2026
Q2 		$2.26K Sell
615
-2,544
-81% -$8.47K ﹤0.01% 1921
2026
Q1 		$9.7K Buy
+3,159
New +$12.2K ﹤0.01% 1272

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Essential Partners's RXRX Position: Q3 2026 in Review

Essential Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 615 shares — an estimated $2.26K sold.

Essential Partners first reported a position in RXRX in Q1 2026 and held it in 2 quarters. The position peaked at $9.7K in Q1 2026. 22 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Essential Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Essential Partners sold 615 Recursion Pharmaceuticals shares in Q3 2026, an estimated $2.26K.
  • Essential Partners first reported a position in Recursion Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • Essential Partners's Recursion Pharmaceuticals position peaked at $9.7K in Q1 2026.
  • 22 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.